Supervisory Board

We are supported by a highly experienced supervisory board with broad industry knowledge

Dr. Gerd Zettlmeissl


Gerd Zettlmeissl has been working in various R&D and General Management positions in the biopharmaceutical and vaccine industry since 1985. His last positions were Managing Director of Chiron Behring, a leading vaccine manufacturer in Germany, and until May 2011, Chief Executive Officer of Intercell, in Austria. During his career, he made major contributions to the discovery, development and registration of a number of biologicals and vaccines.

He currently serves as Non-Executive Director of Aeras, a non-profit organization developing tuberculosis vaccines, and of various biotech companies. Gerd holds a doctoral degree in biochemistry of the University of Regensburg and did a post-doctoral fellowship at the Institute Pasteur Paris in virology between 1983 and 1985.

Jean Bourcereau

Jean is a Managing Partner and President at Ventech. He has been active in the VC industry for the past 20 years, as a co-founder of Ventech. He brings to the management teams, backed by Ventech, his expertise in scaling businesses across multiple industries.

Jean currently serves as a board member for Crocus Technology, Intercloud, Misterb&b, ReachFive, Ogury and Themis. He was instrumental in many of Ventech’s investments over the years including Altitude Télécoms (ILD), Arteris (QCOM), Ateme (ATEME), Ekinops (EKI), Musiwave (MSFT), Muzicall (RNWK), Wengo (VIV) and Withings (NOK).

Fabien Collangettes

Fabien Collangettes is Principal specialized in Deep Tech investments in the Venture Capital team at Omnes Capital. Prior to that, Fabien co-founded a software company (sold to a French ESN) and invested in early stage startups.

Besides Themis, Fabien invested in Sentryo, acquired by Cisco last year, and represents Omnes Capital on the board of Therapixel. Fabien graduated from Supelec and holds a MS from the Imperial College (UK).

Dr. Philippe Dro

Dr. Philippe Dro is currently Chairman, CEO and Director of the Board at Luciole Medical (Zürich, Switzerland), Chairman of Limmatech Biologics (Zürich, Switzerland), member of the Board at Themis Bioscience GmbH, (Austria) as well as Omics SA Bioinformatics (France), a bioinformatic company. He was CEO AND Director at Glycovaxyn AG (Zürich, Switzerland) which was acquired by GSK in 2015. He served on the Board of Aleva Therapeutics SA (Switzerland), Spinevision SA (France), Antares Pharma Ltd (USA), and SkyePharma Ltd (USA).

Dr. Philippe Dro also served as a Chairman and CEO at EndoArt SA (Lausanne, Switzerland) acquired by Allergen in 2007 and as a Chief Financial Officer/Chief Operating Officer at Axovan AG (Basel, Switzerland), and President & Chief Operating Officer. He has a PharmD from Grenoble School of Pharmacy (FRANCE) and a MBA both from Ecole Supérieure de Commerce de Lyon (France) and Cranfield School of Management (UK).

Dr. Iain Dukes

Dr. Iain Dukes joined OrbiMed as a Venture Partner in 2016. He is currently Chairman of Iovance Biotherapeutics (NASQ:IOVA) and serves on the Board of Directors of Ikena Oncology, KaNDy Therapeutics (formerly as Chairman), NeRRe Therapeutics, ReViral Limited and ENYO Therapeutics. He co-founded and is CEO of Theseus Pharmaceuticals and co-founded Kartos Therapeutics and Telios Pharma where he serves as President.

Most recently, he has taken the role of Executive Chairman at Angiex and is founding CEO of the Loch family of companies (Ness Lomond and Eil). Prior to joining OrbiMed, Iain was Senior Vice President of Business Development and Licensing at MSD (known as Merck & Co in the US) where he was responsible for all business development activity for the Merck Research Laboratories division of MSD. Before joining MSD, Iain served as Vice President of External Research and Development at Amgen and previously also held the position of Vice President, Scientific and Technology Licensing at GlaxoSmithKline. Dr. Dukes received a DPhil degree from the University of Oxford where he also received an MA in Jurisprudence.

Dr. Regina Hodits

Regina Hodits is a General Partner at Wellington Partners and represents the Wellington funds on the Boards of Themis, Rigontec, Middle Peak Medical, AYOXXA, and Atopix. She was a founding investor in Sapiens, which was sold to Medtronic, and an external director at GlaxoSmithKline’s Respiratory TA Board. Since joining the industry in 2000, she has become an influential investor in the European venture capital industry, focusing on early-stage and growth deals in Life Sciences.

Further stations of her career were Atlas Venture and Apax Partners, for which she served on several Boards, including Bicycle Therapeutics, F-star (partly acquired by BMS), U3 Pharma (acquired by Daiichi Sankyo), Nitec Pharma (now part of Horizon Pharma NASDAQ HZPN), Egalet (NASDAQ: EGLT), and Novamed, (acquired by SciClone, NASDAQ SCLN). Regina Hodits studied chemical engineering in Vienna and holds a Ph.D. in biochemistry. She started to build her extensive network in the global healthcare industry during her tenure at McKinsey.

Dr. Jean Paul Prieels

After ten years at academia, Jean Paul Prieels started his industrial career at Petrofina in 1983 as Biotechnology Manager and joined GlaxoSmithKline Biologicals in 1987. His responsibilities gradually expanded to lead the vaccine preclinical R&D development activities in Rixensart, Belgium. He retired as Senior Vice President of Research & Development at GlaxoSmithKline Biologicals in 2011.

His career spans from basic research to applied research and product development. He was instrumental in the development of several commercially available vaccines, such as Rotarix, Cervarix and Synflorix. Today he is involved as director or member of the advisory board in biotech and non-profit organizations. Jean Paul Prieels holds a PhD in Biochemistry from Université Libre de Bruxelles, Belgium.

Glenn Rockman

Glenn is Managing Partner at Adjuvant Capital. He founded Adjuvant in 2018 to build an investment firm that champions the most promising life science technologies for high-burden and neglected public health challenges. Prior to Adjuvant, he launched and then co-managed the Global Health Investment Fund (GHIF), which was created by the Bill & Melinda Gates Foundation and J.P. Morgan to demonstrate that historically overlooked diseases can present compelling double-bottom-line investment opportunities. Recent successes from his investment activity include the first new FDA-approved treatment for river blindness in 20 years (with a Priority Review Voucher sold to Novo Nordisk in 2019), the world’s most widely-used cholera vaccine (Euvichol-Plus®), and an innovative cataract surgery device (miLOOP, acquired by Carl Zeiss Meditec in 2018).

Prior to his roles at GHIF and now Adjuvant, Glenn spent more than a decade as an investment banker at J.P. Morgan, where his practice focused on serving the financing needs of research institutions, charitable foundations, universities, and other non-profit organizations. He earned an AB in public policy from the Woodrow Wilson School of Public & International Affairs at Princeton University.

Dr. Walter Stockinger

Walter is managing partner of Hadean Ventures. After obtaining a PhD at the University of Vienna, he started his career as a post-doctoral scientist at Harvard University. Subsequently, he joined the Boston Consulting Group as a member of the Healthcare Practice Team, where he advised pharmaceutical companies and PE firms on commercial projects and M&A transactions. In 2009 Walter joined the London office of one of the largest specialist healthcare VC firms. Being responsible for deal sourcing, due diligence and exit management, Walter gained significant experience by successfully investing into and exiting portfolio companies.

In 2017 Walter co-founded Hadean Ventures, a European Life Science VC with offices in Oslo and Stockholm. Hadean invests into the clinical and commercial development of innovative healthcare products and supports young companies with its strong experience in the healthcare industry and its extensive network to potential partners and acquirers.